Everything below concerns SR9009. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
== Isotope ratio measurement == The relative abundances of different isotopes are then used to describe the chemical fractionation of different isotopes, travel in different reservoirs of non-radiogenic isotopes, and age or origins of solar system objects by the presence of radiogenic daughter isotopes. Elemental analysis is a predominant application of TIMS as it gives reliable isotopic ratios. Following the trend of decreasing ionization energy, elements located towards the bottom left of the periodic table are viable for TIMS. In addition, the high electron affinity seen towards the upper right of the periodic table makes these nonmetals excellent candidates. The technique is used extensively in isotope geochemistry, geochronology, and in cosmochemistry. Quantitative isotope ratio techniques include isotope dilution thermal ionization mass spectrometry (ID-TIMS) and chemical abrasion thermal ionization mass spectrometry (CA-TIMS). Isotope dilution method is used because the signal intensity in TIMS isn't proportional to the amount that is placed into TIMS. For age dating, mass spectrometers with magnetic sectors have better precision than a quadrupole mass spectrometer or quadrupole mass analyzer. Inductively coupled plasma-quadrupole mass spectrometers allows for an even higher precision of detecting the change of isotopic ratios by radioactive decay. The more precision means the higher resolution in age dating.
Commission A1: Cryophysics and Cryoengineering Commission A1 on Cryophysics and Cryoengineering deals with research, development and industrial activities at the lowest temperatures, including low-temperature physics, applications of superconductivity and helium cryogenics.
In late 1988, tensions between the United States and Panama were extremely high with the Panamanian leader, Manuel Noriega, calling for the dissolution of the agreement that allowed the United States to have bases in his country. In December 1989 President George H. W. Bush activated the planning section for Operation Just Cause/Promote Liberty. Just Cause was the portion of the mission to depose Noriega and return Panama to democracy. Originally scheduled to begin at 0200 hrs. on 20 December, it actually kicked off at 2315 hrs when part of a Special Forces detachment that was waiting for the signal to begin was discovered above a gate above a Panamanian checkpoint. Just Cause was the first mission to have a very large contingent of Special Operations Forces on the ground. The units that were involved with the mission were as follows: Task Force Green (Delta Force), Task Force Black (7th SFG), 5th SFG, 3rd SFG, 4th PSYOP Group, the reinforced 1st Brigade of the 82nd Airborne Division, and all three battalions of the 75th Rangers, and numerous other units from other forces such as the Navy SEALs, Marine Force Recon, and Air Force Combat Control Teams. Of the 23 US troops who died in the invasion four were Navy SEALs. The invasion was successful at deposing Noriega, but led to widespread looting and lawlessness in the following weeks.
=== Liver === The human liver is particularly known for its ability to regenerate, and is capable of doing so from only one quarter of its tissue, due chiefly to the unipotency of hepatocytes. Resection of liver can induce the proliferation of the remaining hepatocytes until the lost mass is restored, where the intensity of the liver's response is directly proportional to the mass resected. For almost 80 years surgical resection of the liver in rodents has been a very useful model to the study of cell proliferation.
Sources: en.wikipedia.org
==== Revolts of the era of the Spring of Nations ==== The planned national uprising failed to materialize because the authorities in the partitions found out about secret preparations. The Greater Poland uprising ended in a fiasco in early 1846. In the Kraków uprising of February 1846, patriotic action was combined with revolutionary demands, but the result was the incorporation of the Free City of Cracow into the Austrian Partition. The Austrian officials took advantage of peasant discontent and incited villagers against the noble-dominated insurgent units. This resulted in the Galician slaughter of 1846, a large-scale rebellion of serfs seeking relief from their post-feudal condition of mandatory labor as practiced in folwarks. The uprising freed many from bondage and hastened decisions that led to the abolition of Polish serfdom in the Austrian Empire in 1848. A new wave of Polish involvement in revolutionary movements soon took place in the partitions and in other parts of Europe in the context of the Spring of Nations revolutions of 1848 (e.g. Józef Bem's participation in the revolutions in Austria and Hungary). The 1848 German revolutions precipitated the Greater Poland uprising of 1848, in which peasants in the Prussian Partition, who were by then largely enfranchised, played a prominent role.
A&W is a fast-food restaurant chain in Canada, franchised by A&W Food Services of Canada Inc. The company was initially a subsidiary of the U.S.-based A&W Restaurants chain, with the subsidiary opening its first franchise in Winnipeg in 1956. In 1972, Unilever acquired A&W's Canadian operations, leading to the subsidiary's separation from the U.S.-based company. In 1995, a Canadian management group made up of A&W franchisees took ownership of the chain from Unilever. A&W Food Services of Canada Inc. is a publicly traded company headquartered in North Vancouver. As of 2022, A&W was Canada's second-largest fast-food hamburger chain, with 1,029 franchises, after McDonald's.
== History == Ketobemidone was first synthesized in 1942 by Eisleb and colleagues, at the laboratory of I.G. Farbenindustrie at Hoechst during the Second World War. The first study of it in humans was published in 1946, and it was introduced in clinical medicine shortly after. It was not in clinical use in the United States when the Controlled Substances Act 1970 was promulgated and was assigned to Schedule I with an ACSCN of 9628. As of 2013, no annual manufacturing quota was assigned by the DEA. Pfizer manufactures ketobemidone under the tradenames Ketogan and Ketorax. It is available as tablets, suppositories, and injection fluid. A sustained release formulation, sold as Ketodur, exists in some countries and contains 10 or 25 mg ketobemidone.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.